uploads///Chart

How AstraZeneca’s Oncology Products Performed in 4Q17

By

Updated

Oncology segment

AstraZeneca’s (AZN) oncology products include legacy oncology products as well as new oncology products. The oncology segment reported revenues of $1.1 billion during 4Q17, a 19% increase in operating revenues as compared to 4Q16. The growth was driven by increased sales of Faslodex, Iressa, Lynparza, and Tagrisso. However, the lower sales of Arimidex, Zoladex, and Casodex partially offset the growth during 4Q17. The chart below compares revenues for oncology products since 1Q17.

Article continues below advertisement

Tagrisso

Tagrisso reported revenues of $304 million during 4Q17, a ~105% increase in operating revenues as compared to 4Q16. The growth was driven by increased sales across all the markets worldwide. Tagrisso saw sales of $128 million in the US during 4Q17, a 73% increase as compared to 4Q16. The European markets reported Tagrisso sales of $63 million during 4Q17, a ~115% increase in operating revenues as compared to 4Q16. The established rest of the world markets reported Tagrisso sales of $63 million, while the emerging markets reported Tagrisso sales of $50 million during 4Q17.

Tagrisso is approved for the treatment of EGFR T790M mutation-positive metastatic non-small-cell lung cancer (or NSCLC). Some other drugs for the treatment of NSCLC include Pfizer’s (PFE) Xalkori, Merck’s (MRK) Keytruda, and Bristol-Myers Squibb’s (BMY) Opdivo.

Faslodex

Faslodex, a legacy oncology product, reported revenues of $238 million during 4Q17, a 5% increase in operating revenues as compared to 4Q16. The growth was driven by increased sales of Faslodex in the US markets, emerging markets, and established rest of the world markets, partially offset by lower sales in the European markets. The US markets saw Faslodex sales of $124 million, emerging markets saw Faslodex sales of $27 million, established rest of the world markets saw Faslodex sales of $25 million, and European markets reported Faslodex sales of $62 million during 4Q17.

Article continues below advertisement

Iressa

Iressa reported revenues of $130 million during 4Q17, an 8% increase in operating revenues as compared to 4Q16. The growth was driven by increased sales of Iressa across all major markets worldwide. However, foreign exchange had a negative impact on the revenues from the established rest of the world markets. The US markets saw Iressa sales of $12 million, while the emerging markets reported Iressa sales of $51 million, the European markets reported Iressa sales of $32 million, and the established rest of the world markets reported Iressa sales of $35 million during 4Q17.

Lynparza

Lynparza reported revenues of $100 million during 4Q17, a 58% increase as compared to 4Q16. The growth was driven by increased sales across all the markets worldwide. The US markets reported Lynparza sales of $54 million, while the European markets reported Lynparza sales of $36 million during 4Q17.

Advertisement

More From Market Realist